Determination of β2–microglobulin level as a prognostic marker of chronic lymphocytic leukemia

Abstract

Disease prediction is rather important for the modern medicine. In the age of new and complex prognostic markers, β2–microglobulin is still simple, but important survival predictor in chronic lymphocytic leukemia (CLL) patients. The use of new biological markers is very expensive and not available for routine analysis in all regions. In contrast, β2–MG is significantly cheaper and simpler in its realization, as well as it is affordable for many non-specialized laboratories.Aim. To analyze β2–MG level prognostic significance and its correlation depending on the disease stage, tumor volume and response to treatment in CLL patients.Methods. 98 CLL patients, 37 women aged 42-75 years (average age 62.5 years) and 61 men aged 38-82 years (average age 62.5 years) were examined by us.All the patients had general clinical examination, lymphocytes immunophenotyping in peripheral blood or bone marrow – phenotype СD 5+, СD 19+, СD 20+, СD23+, β2–MG using ECLIA method (Electro-chemiluminescence immunoassay). Cobas 6000, Roche Diagnostics (Switzerland) analyzer and test system were used. Reference values were 0,8–2,2 mg/l.Results. In result of the study of β2–MG level in chronic lymphocytic leukemia (CLL) patients on the different stages of the disease, it was found, that β2–MG level correlates with CLL stage, directly depends on tumor volume, and is a reliable prognostic marker of response to treatment in CLL patients. β2–MG level >3,5 mg/l in blood serum is a bad prognostic predictor, which points to the high risk of disease.Conclusion. β2–MG level correlates with the disease stage, tumor volume, and is a reliable prognostic marker of response to treatment in CLL patients